The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma

Neurological Research

Volumn 34, Issue 3, 2012, Pages 252-261

  D'Amico, Randy ^a   Lei, Liang ^a   Kennedy, Benjamin C ^a   Sisti, Julia ^a   Ebiana, Victoria ^a   Crisman, Celina ^a   Christensen, James G ^b   Gil, Orlando ^a   Rosenfeld, Steven S ^c   Canoll, Peter ^a   Bruce, Jeffrey N ^a  

^a NewYork Presbyterian Hospital   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Glioblastoma; PDGF; Radiation; Radiotherapy; SU1128; Sunitinib; Sutent; VEGF

Indexed keywords

CRE RECOMBINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN P53; SUNITINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLUMINESCENCE; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CHEMORADIOTHERAPY; CONTROLLED STUDY; DRUG FATALITY; DRUG TOLERABILITY; GENE DELETION; GLIOBLASTOMA; HISTOLOGY; MONOTHERAPY; MOUSE; NEURAL STEM CELL; NONHUMAN; PENETRANCE; RADIATION DOSE; RADIATION INJURY;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GLIOBLASTOMA; INDOLES; MICE; MICE, TRANSGENIC; PYRROLES; RADIATION DOSAGE;

EID: 84859299802     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132812Y.0000000005     Document Type: Article

References (49)

1. Primary brain and central nervous sytem tumors diagnosed in the United States in2004-2006. Hinsdale (IL): Central Brain Tumor Registry of the United States; 2010. CBTRUS Statistical Report.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-96.
3. Hovinga KE, Stalpers LJ, van Bree C, Donker M, Verhoeff JJ, Rodermond HM, et al. Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines-a clue to radioresistance? J Neurooncol. 2005;74(2):99-103.
4. Shaifer CA, Huang J, Lin PC. Glioblastoma cells incorporate into tumor vasculature and contribute to vascular radioresistance. Int J Cancer. 2010;127(9):2063-75.
5. Li HF, Kim JS, Waldman T. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol. 2009;4:43.
6. Lerman OZ, Greives MR, Singh SP, Thanik VD, Chang CC, Seiser N, http://www.ncbi.nlm.nih.gov/pubmed?term5%22Brown%20DJ% 22%5BAuthor%5D et al. Low-dose radiation augments vasculogenesis signaling through HIF-1-dependent and-independent SDF-1 induction. Blood. 2010;116(18):3669-76.
7. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999;59(14):3374-8.
8. Lund EL, Høg A, Olsen MW, Hansen LT, Engelholm SA, Kristjansen PE. Differential regulation of VEGF, HIF1alpha and angiopoietin-1,-2 and-4 by hypoxia and ionizing radiation in human glioblastoma. Int J Cancer. 2004;108(6):833-8.
9. Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, et al. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res. 2008;14(7):2210-9.
10. Brown CK, Khodarev NN, Yu J, Moo-Young T, Labay E, Darga TE, et al. Glioblastoma cells block radiation-induced programmed cell death of endothelial cells. FEBS Lett. 2004;565(1-3):167-70.
11. Steiner HH, Karcher S, Mueller MM, Nalbantis E, Kunze S, Herold-Mende C. Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J Neurooncol. 2004;66(1-2):129-38.
12. Mori K, Tani M, Kamata K, Kawamura H, Urata Y, Goto S, et al. Mitogen-activated protein kinase, ERK1/2, is essential for the induction of vascular endothelial growth factor by ionizing radiation mediated by activator protein-1 in human glioblastoma cells. Free Radic Res. 2000;33(2):157-66.
13. Li M, Ping G, Plathow C, Trinh T, Lipson KE, Hauser K, et al. Small molecule receptor tyrosine kinase inhibitor of plateletderived growth factor signaling (SU9518) modifies radiation response in fibroblasts and endothelial cells. BMC Cancer. 2006;6:79.
14. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000;60(19):5565-70.
15. Wachsberger P, Burd R, Dicker AP. Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. Hematol Oncol Clin North Am. 2004;18(5):1039-57.
16. O'Reilly MS. Radiation combined with antiangiogenic and antivascular agents. Semin Radiat Oncol. 2006;16(1):45-50.
17. Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, et al. Differentiation and definition of vasculartargeted therapies. Clin Cancer Res. 2005;11(2 Pt 1):416-20.
18. Chan LW, Camphausen K. Angiogenic tumor markers, antiangiogenic agents and radiation therapy. Expert Rev Anticancer Ther. 2003;3(3):357-66.
19. Teicher BA, Dupuis NP, Robinson MF, Emi Y, Goff DA. Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncol Res. 1995;7(5):237-43.
20. Abdollahi A, Lipson KE, Han X, Krempien R, Trinh T, Weber KJ, et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res. 2003;63(13):3755-63.
21. Wachsberger PR, Burd R, Marero N, Daskalakis C, Ryan A, McCue P, et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res. 2005;11(2 Pt 1):835-42.
22. Ning S, Laird D, Cherrington JM, Knox SJ. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res. 2002;157(1):45-51.
23. Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res. 2002;62(6):1702-6.
24. Lu B, Geng L, Musiek A, Tan J, Cao C, Donnelly E, et al. Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium. Int J Radiat Oncol Biol Phys. 2004;58(3):844-50.
25. Zips D, Eicheler W, Geyer P, Hessel F, Dö rfler A, Thames HD, et al. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. Cancer Res. 2005;65(12):5374-9.
26. Edwards E, Geng L, Tan J, Onishko H, Donnelly E, Hallahan DE. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res. 2002;62(16):4671-7.
27. Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res. 2003;9(6):1957-71.
28. Oertel S, Krempien R, Lindel K, Zabel A, Milker-Zabel S, Bischof M, et al. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec). Strahlenther Onkol. 2006;182(7):400-7.
29. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003;111(9):1287-95.
30. Saharinen P, Alitalo K. Double target for tumor mass destruction. J Clin Invest. 2003;111(9):1277-80.
31. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004;18(2):338-40.
32. Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JV, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007;13(5):1367-73.
33. Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, et al. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007;12(1):107-13.
34. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364(6):501-13.
35. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327-37.
36. Mena AC, Pulido EG, Guillen-Ponce C. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs. 2010;21 Suppl 1:S3-11.
37. Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1-18.
38. Neyns B, Sadones J, Chaskis C, Dujardin M, Everaert H, Lv S, et al. Phase II study of sunitinib malate in patients with recurrent high-grade glioma. J Neurooncol. 2011;103(3):491-501.
39. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 2003;63(14):4009-16.
40. Lei L, Sonabend AM, Guarnieri P, Soderquist C, Ludwig T, Rosenfeld S, et al. Glioblastoma models reveal the connection between adult glial progenitors and the proneural phenotype. PLoS One.2011;6(5):e20041.
41. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys. 1979;5(10):1725-31.
42. Sisti J. 'Abstract 323. Treating a PDGF-Driven Model of Glioblastoma with Sunitinib Slows Tumor Growth and Prolongs Survival But Induces a Marked Increase in Tumor Cell Invasion' Abstracts from the 2009 Joint Meeting of the Society for Neuro-Oncology (SNO) and the American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Section on Tumors: October 22-24, 2009: New Orleans, LA. Neuro Oncol. 2009;11(5):564-699.
43. Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res. 2001;61(6):2413-9.
44. Verhoeff JJ, Stalpers LJ, Claes A, Hovinga KE, Musters GD, Peter Vandertop W, et al. Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma. Eur J Cancer. 2009;45(17):3074-80.
45. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29(2):142-8.
46. Vredenburgh JJ, Desjardins A, Kirkpatrick JP, Reardon DA, Peters KB, Herndon JE 2nd, http://www.ncbi.nlm.nih.gov/ pubmed?term5%22Marcello%20J%22%5BAuthor%5D et al. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2012;82(1):58-66.
47. Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2009;75(1):156-63.
48. Chang JE, Khuntia D, Robins HI, Mehta MP. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clin Adv Hematol Oncol. 2007;5(11):894-902, 907-15.
49. Chahal M, Xu Y, Lesniak D, Graham K, Famulski K, Christensen JG, et al. MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib. Neuro Oncol. 2010;12(8):822-33.